Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of...

Full description

Bibliographic Details
Main Authors: Hugo Marcel Vanderstichele, Charlotte E. Teunissen, Eugeen Vanmechelen
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-12-01
Series:Neurology and Therapy
Subjects:
Assay
Blood
Biomarker panel
β-Amyloid
Tau
Validation
Online Access:https://doi.org/10.1007/s40120-019-00166-3
Description
Summary:Abstract This review aims to document difficulties, limitations, and pitfalls when considering protein analysis in blood samples. It proposes an improved workflow for design, development, and validation of (immuno)assays for blood proteins, without providing reflections on a potential hypothesis of the origin of protein mismetabolism and deposition. There is a special focus on assay development for quantification of β-amyloid (Aβ) and tau in blood for diagnostic use or for integration in clinical trials in the field of Alzheimer’s disease (AD).
ISSN:2193-8253
2193-6536

Similar Items